… to abate toxicities without impairing ICI efficacy in the specific … In metastatic renal cell carcinoma,
the same combination has … efficacy of immune checkpoint blockers targeting PD-1/PD-L1…

… increasingly dependent on pathways governed by the mechanistic target of rapamycin (…
Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal …

… transporter 1 (Glut1) in renal cell carcinoma with T cell function … These studies mostly focus
on the inhibition of the PD-1/PD-… uncouple antigen recognition from CAR activation signaling. …

… which have different survival and toxicity profiles and are often … the effects of IL-6 blockade
as irAE treatment on ICI efficacy. … low-dose everolimus (mTORC1 inhibitor) to anti-PD-1 led to …

… CAR-T cells could decrease the expression of PD-1, LAG-3, and TIM-3 … , lung, liver, and renal
cell carcinomas. Studies showed that … However, the toxicity and possibility of promoting the …

… strategy was recently tested in a KTR with melanoma where PD-1 blockade … that
targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 …

… In terms of ICI treatment strategies, anti-PD-1-related ITP … , their multi-organ drug toxicity
caused by them has gradually … from the lung, head and neck, kidney, bladder, and liver had an …

… Categorical variables were compared between toxicities using … cases of liver rejections and
two cases of kidney rejections. … cells and the PD-1/PD-L1 signaling pathway are responsible …

… expression of immune checkpoints, including PD-1, 2B4, TIM-3… toxicity. When the SREBP-SCAP
axis was inhibited, in addition to tumor growth attenuation, immunotherapy effectiveness …

… the efficacy of immunotherapy and facilitating the immune evasion of tumor cells [35, 36].
Predicting the efficacy of PD-1 … molecule inhibitors targeting the PI3K/AKT/mTOR pathway have …